---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-001143"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2026-08-25T12:31:04+00:00"
generated_at: "2026-08-25T12:35:12.533471+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anavex Q3 net income $7.8M on comp reversal; advances FDA/EMA regulatory plans

## Summary
- Q3 FY2026 net income $7.8M ($0.08/share) vs net loss $13.2M ($0.16/share) in Q3 FY2025.
- Cash $118.3M at June 30, 2026 (vs $102.6M at Sept 30, 2025); funds ops into mid-late FY2028.
- Reversal of $17.4M stock-based comp (G&A $7.5M, R&D $9.9M) from employee terminations, mainly former CEO.
- Submitted all AD clinical data to FDA; FDA Phase 3 AD-005 design talks planned; EMA scientific advice received June 2026.
- Rett Phase 3 RS-005 (~170 pts): FDA meeting requested on pediatric inclusion; Fragile X IND due Sept; 10-Q filings pending.

## SEC filing metadata
- accession: 0001731122-26-001143
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2026-08-25T12:31:04+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112226001143/0001731122-26-001143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112226001143/e7897_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-001143
- JSON: https://secwatch.observer/filing/0001731122-26-001143.json
- Plain text: https://secwatch.observer/filing/0001731122-26-001143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.